Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates

Patent metadata

Field	Value
Publication number	US-2016129130-A1
Application number	US-201514938658-A
Country	US
Kind code	A1
Filing date	Nov 11, 2015
Priority date	Jan 9, 2009
Publication date	May 12, 2016
Grant date	—

Abstract

Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.

First claim

1 - 25 . (canceled)

26 . A method for treating a CD30-expressing hematologic cancer in a human subject, the method comprising administering to a subject in need thereof a dose of a pharmaceutical composition comprising cAC10-MC-vc-PAB-MMAE, wherein the administered dose of cAC10-MC-vc-PAB-MMAE is 0.3 to 2.0 mg/kg of the subject's body weight and the pharmaceutical composition is administered every three to six weeks as a monotherapy.

27 . The method of claim 26 , wherein the CD30-expressing hematologic cancer is Hodgkin Lymphoma.

28 . The method of claim 26 , wherein the CD30-expressing hematologic cancer is anaplastic large cell lymphoma.

29 . The method of claim 26 , wherein the dose of cAC10-MC-vc-PAB-MMAE is 1.8 mg/kg.

30 . The method of claim 29 , wherein the dose is administered every three weeks.

31 . The method of claim 27 , wherein the dose of cAC10-MC-vc-PAB-MMAE is 1.8 mg/kg of the human subject's body weight and is administered every three weeks.

32 . The method of claim 28 , wherein the dose of cAC10-MC-vc-PAB-MMAE is 1.8 mg/kg of the human subject's body weight and is administered every three weeks.

33 . The method of claim 26 , wherein cAC10-MC-vc-PAB-MMAE is administered at 1.8 mg/kg of the subject's body weight every three weeks as a monotherapy following administering cAC10-MC-vc-PAB-MMAE at a weekly dose of 0.8 mg/kg to 1.2 mg/kg for at least three weeks as a monotherapy.

Assignees

• Seattle Genetics Inc

Inventors

• Sievers Eric
• Kennedy Dana
• Ihle Nathan
• Sun Michael

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P35/02

  specific for leukemia · CPC title

• C07K2317/56

  variable (Fv) region, i.e. VH and/or VL · CPC title

• A61K47/64

  Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65) · CPC title

• C07K2317/77

  Internalization into the cell · CPC title